Last reviewed · How we verify

NCT05845658

Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Anxiety: A Randomized Clinical Trial

Completed NA Last updated 23 January 2024
What this trial tests

NA trial testing Active VeNS in Anxiety in 60 participants. Completed in 10 June 2023.

Timeline
25 October 2022
Primary endpoint
10 June 2023
10 June 2023

Quick facts

Lead sponsorNeurovalens Ltd.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment60
Start date25 October 2022
Primary completion10 June 2023
Estimated completion10 June 2023
Sites1 location across India

Drugs / interventions tested

Conditions studied

Sponsor

Neurovalens Ltd.

Who can join

Adults 22 to 80, any sex, with Anxiety. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study will be conducted at the Department of Physiology in collaboration with the Department of Psychiatry of R.D. Gardi Medical College, Ujjain, Madhya Pradesh. This double-blind randomized controlled trial will remotely enroll 60 subjects. Each participant will complete 20 stimulation sessions at a rate of 3-5 sessions per week. Each session will be 30 minutes on the day of usage. The study will be randomized with a 1:1 active; or sham control allocation. Endpoint analysis will be performed upon completion of the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Anxiety

Currently open trials in the same condition.

Other Neurovalens Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05845658.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing